CagriSema

Medicine & Biotech · covered by 4 outlets this week · tracked since 2026-10-29

Press: 2 specialist 2 independent outlet-days

Background

Cagrilintide/semaglutide, known as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It has been proposed as a follow-on to semaglutide (alone) or tirzepatide in treatments for obesity and type II diabetes. Wikipedia ↗

Written by the Alivewire editors from the coverage below, 19h ago. Not medical advice; how the ratings work.

Coverage

study

Novo takes 26 obesity studies to ObesityWeek

Longevity.Technology · 1d ago

ATX-304, Cagrilintide, Tesa

Reddit r/Biohackers · 9d ago

studymeta-analysis

CagriSema 2.4/2.4 mg versus CagriSema 1.0/1.0 mg in adults with type 2 diabetes: a dose-comparison systematic review and meta-analysis of randomized controlled trials

medRxiv (all subjects) · 11d ago

CagriSema lowers weight for women across reproductive lifespan

Healio · 13d ago

Sources

CagriSema

Background

Coverage